Nelarabine and Daratumumab Produce Promising Outcomes in T-ALL Trials
Cancer Network,
"...Improving frontline therapy to prevent relapse remains the optimal approach for treating patients with T-ALL.
Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL
OncLive,
Kristen O’Dwyer, MD Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients…
Targeted Therapies Continue to Improve OS in T-Cell Acute Lymphoblastic Leukemia
Oncology Nursing News,
Survival rates in T-cell acute lymphoblastic leukemia (T-ALL), although formally inferior to survival rates in B-cell acute…
Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics
Cancer Network,
Despite having a previous gap in survival rates, patients with T-cell acute lymphoblastic leukemia (T-ALL) and those with B-cell…